Uterine Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Cervical Cancer (106)

›

KRAS G12D	Endometrial Cancer	KRAS G12D	Endometrial Cancer	trametinib + BI-3406 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) trametinib + BI-3406 Sensitive : D AACR 2023 - 1wk	trametinib + BI-3406 Sensitive: D – Preclinical AACR 2023 - 1 week trametinib + BI-3406 Sensitive : D AACR 2023 - 1 week - (New D)
CLDN6 expression	Endometrial Cancer	CLDN6 expression	Endometrial Cancer	CTIM-76 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) CTIM-76 Sensitive : D AACR 2023 - 1wk	CTIM-76 Sensitive: D – Preclinical AACR 2023 - 1 week CTIM-76 Sensitive : D AACR 2023 - 1 week - (New D)
CLDN18.2 expression	Endometrial Cancer	CLDN18.2 expression	Endometrial Cancer	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical Clin Cancer Res - 2 weeks (New D) CLDN18.2-targeted antibody-drug conjugate Sensitive : D Clin Cancer Res - 2wk	CLDN18.2-targeted antibody-drug conjugate Sensitive: D – Preclinical Clin Cancer Res - 2 weeks CLDN18.2-targeted antibody-drug conjugate Sensitive : D Clin Cancer Res - 2 weeks - (New D)
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	dostarlimab Sensitive: A1 - Approval dostarlimab Sensitive : A1	dostarlimab Sensitive: A1 - Approval dostarlimab Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
HER-2 expression	Endometrial Adenocarcinoma	HER-2 expression	Endometrial Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
NTRK1 fusion	Endometrial Cancer	NTRK1 fusion	Endometrial Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Endometrial Cancer	NTRK2 fusion	Endometrial Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Endometrial Cancer	NTRK3 fusion	Endometrial Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	cisplatin + paclitaxel + SGN-15 Sensitive: A2 - Guideline cisplatin + paclitaxel + SGN-15 Sensitive : A2	cisplatin + paclitaxel + SGN-15 Sensitive: A2 - Guideline cisplatin + paclitaxel + SGN-15 Sensitive : A2
NTRK1 fusion	Endometrial Cancer	NTRK1 fusion	Endometrial Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	carboplatin + docetaxel Sensitive: A2 - Guideline carboplatin + docetaxel Sensitive : A2	carboplatin + docetaxel Sensitive: A2 - Guideline carboplatin + docetaxel Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
HER-2 positive	Endometrial Cancer	HER-2 positive	Endometrial Cancer	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
TMB-H	Endometrial Cancer	TMB-H	Endometrial Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	cisplatin + ifosfamide Sensitive: A2 - Guideline cisplatin + ifosfamide Sensitive : A2	cisplatin + ifosfamide Sensitive: A2 - Guideline cisplatin + ifosfamide Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	paclitaxel + ifosfamide Sensitive: A2 - Guideline paclitaxel + ifosfamide Sensitive : A2	paclitaxel + ifosfamide Sensitive: A2 - Guideline paclitaxel + ifosfamide Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	cisplatin + SGN-15 Sensitive: A2 - Guideline cisplatin + SGN-15 Sensitive : A2	cisplatin + SGN-15 Sensitive: A2 - Guideline cisplatin + SGN-15 Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	SGN-15 Sensitive: A2 - Guideline SGN-15 Sensitive : A2	SGN-15 Sensitive: A2 - Guideline SGN-15 Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	temsirolimus Sensitive: A2 - Guideline temsirolimus Sensitive : A2	temsirolimus Sensitive: A2 - Guideline temsirolimus Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
NTRK3 fusion	Endometrial Cancer	NTRK3 fusion	Endometrial Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Endometrial Cancer	NTRK2 fusion	Endometrial Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	tamoxifen + medroxyprogesterone Sensitive: A2 - Guideline tamoxifen + medroxyprogesterone Sensitive : A2	tamoxifen + medroxyprogesterone Sensitive: A2 - Guideline tamoxifen + medroxyprogesterone Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2

Uterine Cancer

Associations(208)

Associations
(208)